APTEVO THERAPEUTICS INC (APVO)
US03835L3069 - Common Stock
Taking everything into account, APVO scores 2 out of 10 in our fundamental rating. APVO was compared to 564 industry peers in the Biotechnology industry. While APVO seems to be doing ok healthwise, there are quite some concerns on its profitability. APVO does not seem to be growing, but still is valued expensively.
1. Profitability
1.1 Basic Checks
APVO had negative earnings in the past year.
In the past year APVO has reported a negative cash flow from operations.
In the past 5 years APVO reported 4 times negative net income.
In the past 5 years APVO always reported negative operating cash flow.
1.2 Ratios
APVO has a worse Return On Assets (-153.26%) than 85.82% of its industry peers.
APVO has a worse Return On Equity (-442.72%) than 78.82% of its industry peers.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| ROA | -153.26% | ||
| ROE | -442.72% | ||
| ROIC | N/A |
ROA(3y)-32.3%
ROA(5y)-41.16%
ROE(3y)-812.67%
ROE(5y)-577.31%
ROIC(3y)N/A
ROIC(5y)N/A
1.3 Margins
The Profit Margin and Operating Margin and Gross Margin are not available for APVO so they could not be analyzed.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| OM | N/A | ||
| PM (TTM) | N/A | ||
| GM | N/A |
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
2. Health
2.1 Basic Checks
APVO does not have a ROIC to compare to the WACC, probably because it is not profitable.
The number of shares outstanding for APVO has been increased compared to 1 year ago.
The number of shares outstanding for APVO has been increased compared to 5 years ago.
APVO has no outstanding debt. Therefor its Debt/Equity and Debt/FCF ratios are 0 and belong to the best of the industry.
2.2 Solvency
APVO has an Altman-Z score of -23.04. This is a bad value and indicates that APVO is not financially healthy and even has some risk of bankruptcy.
APVO has a worse Altman-Z score (-23.04) than 88.69% of its industry peers.
APVO has no outstanding debt. Therefor its Debt/Equity and Debt/FCF ratios are 0 and belong to the best of the industry.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Debt/Equity | 0 | ||
| Debt/FCF | N/A | ||
| Altman-Z | -23.04 |
ROIC/WACCN/A
WACC6.34%
2.3 Liquidity
APVO has a Current Ratio of 1.92. This is a normal value and indicates that APVO is financially healthy and should not expect problems in meeting its short term obligations.
APVO's Current ratio of 1.92 is on the low side compared to the rest of the industry. APVO is outperformed by 77.20% of its industry peers.
A Quick Ratio of 1.92 indicates that APVO should not have too much problems paying its short term obligations.
With a Quick ratio value of 1.92, APVO is not doing good in the industry: 75.22% of the companies in the same industry are doing better.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Current Ratio | 1.92 | ||
| Quick Ratio | 1.92 |
3. Growth
3.1 Past
The Earnings Per Share has grown by an impressive 81.88% over the past year.
Looking at the last year, APVO shows a very negative growth in Revenue. The Revenue has decreased by -100.00% in the last year.
EPS 1Y (TTM)81.88%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%97.82%
Revenue 1Y (TTM)-100%
Revenue growth 3YN/A
Revenue growth 5YN/A
Sales Q2Q%N/A
3.2 Future
The Earnings Per Share is expected to grow by 19.42% on average over the next years. This is quite good.
No Revenue estimates are available, so we could not analyze the future revenue growth and evolution.
EPS Next Y-893.05%
EPS Next 2Y-82.79%
EPS Next 3Y-30.22%
EPS Next 5Y19.42%
Revenue Next YearN/A
Revenue Next 2YN/A
Revenue Next 3YN/A
Revenue Next 5YN/A
3.3 Evolution
No Revenue estimates are available, so we could not analyze the future revenue growth and evolution.
4. Valuation
4.1 Price/Earnings Ratio
The Price/Earnings Ratio is negative for APVO. In the last year negative earnings were reported.
Besides the negative Price/Earnings Ratio, also the Forward Price/Earnings Ratio is negative for APVO. No positive earnings are expected for the next year.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PE | N/A | ||
| Fwd PE | N/A |
4.2 Price Multiples
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| P/FCF | N/A | ||
| EV/EBITDA | N/A |
4.3 Compensation for Growth
APVO's earnings are expected to decrease with -30.22% in the coming years. This may justify a cheaper valuation.
PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2Y-82.79%
EPS Next 3Y-30.22%
5. Dividend
5.1 Amount
No dividends for APVO!.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Dividend Yield | N/A |
APTEVO THERAPEUTICS INC
NASDAQ:APVO (1/3/2025, 8:20:14 PM)
4.58
+0.01 (+0.22%)
Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS IndustryBiotechnology
Earnings (Last)
Earnings (Next)
Inst Owners14.61%
Inst Owner Change0%
Ins Owners0.04%
Ins Owner Change0.1%
Market Cap2.29M
Analysts82.5
Price Target208.85 (4460.04%)
Short Float %N/A
Short Ratio0.03
Dividend
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Dividend Yield | N/A |
Dividend Growth(5Y)N/A
DPN/A
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)2
Avg EPS beat(2)45.29%
Min EPS beat(2)24.06%
Max EPS beat(2)66.52%
EPS beat(4)3
Avg EPS beat(4)29.39%
Min EPS beat(4)-7.67%
Max EPS beat(4)66.52%
EPS beat(8)7
Avg EPS beat(8)101.33%
EPS beat(12)10
Avg EPS beat(12)66.79%
EPS beat(16)10
Avg EPS beat(16)34.32%
Revenue beat(2)N/A
Avg Revenue beat(2)N/A
Min Revenue beat(2)N/A
Max Revenue beat(2)N/A
Revenue beat(4)N/A
Avg Revenue beat(4)N/A
Min Revenue beat(4)N/A
Max Revenue beat(4)N/A
Revenue beat(8)N/A
Avg Revenue beat(8)N/A
Revenue beat(12)N/A
Avg Revenue beat(12)N/A
Revenue beat(16)N/A
Avg Revenue beat(16)N/A
PT rev (1m)2113.51%
PT rev (3m)2113.51%
EPS NQ rev (1m)0%
EPS NQ rev (3m)0%
EPS NY rev (1m)-3600%
EPS NY rev (3m)-3441.87%
Revenue NQ rev (1m)N/A
Revenue NQ rev (3m)N/A
Revenue NY rev (1m)N/A
Revenue NY rev (3m)N/A
Valuation
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PE | N/A | ||
| Fwd PE | N/A | ||
| P/S | N/A | ||
| P/FCF | N/A | ||
| P/OCF | N/A | ||
| P/B | 0.38 | ||
| P/tB | 0.38 | ||
| EV/EBITDA | N/A |
EPS(TTM)-18.26
EYN/A
EPS(NY)-217.57
Fwd EYN/A
FCF(TTM)-45.89
FCFYN/A
OCF(TTM)-45.89
OCFYN/A
SpS0
BVpS12.21
TBVpS12.21
PEG (NY)N/A
PEG (5Y)N/A
Profitability
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| ROA | -153.26% | ||
| ROE | -442.72% | ||
| ROCE | N/A | ||
| ROIC | N/A | ||
| ROICexc | N/A | ||
| ROICexgc | N/A | ||
| OM | N/A | ||
| PM (TTM) | N/A | ||
| GM | N/A | ||
| FCFM | N/A |
ROA(3y)-32.3%
ROA(5y)-41.16%
ROE(3y)-812.67%
ROE(5y)-577.31%
ROIC(3y)N/A
ROIC(5y)N/A
ROICexc(3y)N/A
ROICexc(5y)N/A
ROICexgc(3y)N/A
ROICexgc(5y)N/A
ROCE(3y)N/A
ROCE(5y)N/A
ROICexcg growth 3YN/A
ROICexcg growth 5YN/A
ROICexc growth 3YN/A
ROICexc growth 5YN/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
F-Score3
Asset Turnover0
Health
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Debt/Equity | 0 | ||
| Debt/FCF | N/A | ||
| Debt/EBITDA | N/A | ||
| Cap/Depr | N/A | ||
| Cap/Sales | N/A | ||
| Interest Coverage | N/A | ||
| Cash Conversion | N/A | ||
| Profit Quality | N/A | ||
| Current Ratio | 1.92 | ||
| Quick Ratio | 1.92 | ||
| Altman-Z | -23.04 |
F-Score3
WACC6.34%
ROIC/WACCN/A
Cap/Depr(3y)21.85%
Cap/Depr(5y)15.73%
Cap/Sales(3y)N/A
Cap/Sales(5y)N/A
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)81.88%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%97.82%
EPS Next Y-893.05%
EPS Next 2Y-82.79%
EPS Next 3Y-30.22%
EPS Next 5Y19.42%
Revenue 1Y (TTM)-100%
Revenue growth 3YN/A
Revenue growth 5YN/A
Sales Q2Q%N/A
Revenue Next YearN/A
Revenue Next 2YN/A
Revenue Next 3YN/A
Revenue Next 5YN/A
EBIT growth 1Y8.71%
EBIT growth 3YN/A
EBIT growth 5YN/A
EBIT Next YearN/A
EBIT Next 3YN/A
EBIT Next 5YN/A
FCF growth 1Y-15.81%
FCF growth 3YN/A
FCF growth 5YN/A
OCF growth 1Y-18.95%
OCF growth 3YN/A
OCF growth 5YN/A